The Senate health committee added to FDA user fee legislation Thursday (May 11) an FDA-centric alternative to state Right to Try laws that aims to expand patients' access to experimental treatments within the current regulatory structure. The amendment expands clinical trial eligibility for experimental treatments, gives patients more information on trial eligibility criteria and trial progress, and lets drug manufacturers include certain phase I trial products in their expanded access programs. But the Goldwater Institute, which has pushed state and...